ROCCI, LAURA
 Distribuzione geografica
Continente #
AS - Asia 1.964
NA - Nord America 186
EU - Europa 95
AF - Africa 8
SA - Sud America 7
OC - Oceania 1
Totale 2.261
Nazione #
SG - Singapore 1.802
US - Stati Uniti d'America 173
CN - Cina 83
HK - Hong Kong 66
IT - Italia 34
GB - Regno Unito 21
DE - Germania 15
CA - Canada 7
IN - India 5
MX - Messico 5
NL - Olanda 5
JP - Giappone 4
BR - Brasile 3
EC - Ecuador 3
ES - Italia 3
FI - Finlandia 3
PL - Polonia 3
ZA - Sudafrica 3
FR - Francia 2
GH - Ghana 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
BD - Bangladesh 1
CM - Camerun 1
CZ - Repubblica Ceca 1
DM - Dominica 1
HU - Ungheria 1
IE - Irlanda 1
LT - Lituania 1
LU - Lussemburgo 1
RW - Ruanda 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
UA - Ucraina 1
VE - Venezuela 1
Totale 2.261
Città #
Singapore 74
Hong Kong 64
Hefei 38
Ashburn 32
Boardman 29
London 19
Beijing 15
Dallas 14
Shanghai 11
San Francisco 7
Milan 6
Munich 6
Toronto 6
Rome 5
Amsterdam 4
Brooklyn 4
Council Bluffs 4
Pune 4
Tokyo 4
Atlanta 3
Canzo 3
Johannesburg 3
Los Angeles 3
Mexico City 3
Tivoli 3
Warsaw 3
Accra 2
Ancona 2
Boston 2
Chieti 2
Florence 2
Hangzhou 2
Natick 2
Seattle 2
São Paulo 2
Turku 2
Washington 2
West Jordan 2
Andover 1
Ankara 1
Bethesda 1
Brno 1
Canberra 1
Cerveteri 1
Charlotte 1
Chengdu 1
Chennai 1
Chicago 1
Coro 1
Dongguan 1
Dubai 1
Dublin 1
Freetown 1
Helsinki 1
Juneau 1
Kigali 1
Lancaster 1
Lianyun 1
Luxembourg 1
Maribor 1
Melilli 1
Montreal 1
New York 1
Orem 1
Paris 1
Portici 1
Redmond 1
Redwood City 1
Roseau 1
Salt Lake City 1
San Gavino Monreale 1
Santa Clara 1
Santa Teresa di Riva 1
Secaucus 1
Shijiazhuang 1
St Louis 1
Topeka 1
Vienna 1
Volta Redonda 1
West Chester 1
Wuxi 1
Yantai 1
Yaoundé 1
Zaozhuang 1
Totale 437
Nome #
S-Adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury 199
Survey on learning needs and preferred sources of information to meet these needs in Italian oncology patients receiving chemotherapy 182
Bisphosphonates: new antiangiogenic molecules in cancer treatment? 182
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients 181
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients 177
Docetaxel induced pericardial effusion 165
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients 140
Scientific Evidence for Non-Pharmacological Management of the Main Side-Effects of Antineoplastic Drugs in Colorectal Cancer Patients. [Evidenze scientifiche per la gestione non farmacologica dei principali effetti collaterali della terapia antineoplastica nei pazienti con cancro colon-rettale] 116
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome 108
Prospective observational multicentric case-control study about 'fatigue' in patients with history of breast cancer 107
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients 94
Meeting information needs on cancer-related fatigue: an exploration of views held by Italian patients and nurses 92
In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients 91
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 88
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients 78
Fatal thrombocytopenia and thrombocytopathia: An unusual onset of non small cell lung cancer 77
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients 71
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 66
Repeated intermittent low-dose therapy with zoledronic Acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients 52
Totale 2.266
Categoria #
all - tutte 10.592
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.592


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202257 0 0 5 1 1 2 2 4 2 3 3 34
2022/202318 4 1 6 0 0 0 0 2 2 1 2 0
2023/202487 4 8 2 11 8 30 1 12 1 4 2 4
2024/20251.958 13 7 34 5 7 33 9 6 37 120 733 954
2025/2026146 59 43 21 23 0 0 0 0 0 0 0 0
Totale 2.266